.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chubb
Daiichi Sankyo
McKesson
Fuji
US Department of Justice
Federal Trade Commission
McKinsey
Mallinckrodt
Dow
Accenture

Generated: November 18, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,230,012

« Back to Dashboard

Which drugs does patent 7,230,012 protect, and when does it expire?


Patent 7,230,012 protects THALOMID and is included in one NDA. There have been three Paragraph IV challenges on Thalomid.

This patent has twenty-six patent family members in nineteen countries.

Summary for Patent: 7,230,012

Title:Pharmaceutical compositions and dosage forms of thalidomide
Abstract:Pharmaceutical compositions and single unit dosage forms of thalidomide and pharmaceutically acceptable prodrugs, salts, solvates, hydrates, or clathrates are disclosed. Also disclosed are methods of treating and preventing diseases and conditions such as, but not limited to, leprosy, chronic graft-vs-host disease, rheumatoid arthritis, sarcoidosis, an inflammatory condition, inflammatory bowel disease, and cancer using the novel dosage forms disclosed herein.
Inventor(s): D'Angio; Paul (Basking Ridge, NJ), McCarty; John (Miami Springs, FL)
Assignee: Celgene Corporation (Summit, NJ)
Application Number:10/608,077
Patent Claim Types:
see list of patent claims
Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Celgene
THALOMID
thalidomide
CAPSULE;ORAL020785-001Jul 16, 1998RXYesNo► Subscribe► SubscribeY
Celgene
THALOMID
thalidomide
CAPSULE;ORAL020785-002Jan 17, 2003RXYesNo► Subscribe► SubscribeY
Celgene
THALOMID
thalidomide
CAPSULE;ORAL020785-003Jan 17, 2003RXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 7,230,012

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,006,267Pharmaceutical compositions and dosage forms of thalidomide► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,230,012

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
TaiwanI377062► Subscribe
TaiwanI359659► Subscribe
Taiwan200731973► Subscribe
Slovenia1562556► Subscribe
Taiwan200505449► Subscribe
Portugal1562556► Subscribe
New Zealand540545► Subscribe
MexicoPA05005162► Subscribe
South Korea20050086624► Subscribe
South Korea100671366► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Merck
Argus Health
Dow
Colorcon
Fuji
Cerilliant
Cantor Fitzgerald
Chinese Patent Office
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot